Literature DB >> 31430018

Prevalence of co-occurring psychiatric disorders in adults and adolescents with intellectual disability: A systematic review and meta-analysis.

Mario G Mazza1, Aurora Rossetti1, Giovanna Crespi2, Massimo Clerici1.   

Abstract

BACKGROUND: Subjects with intellectual disability (ID) are vulnerable to experience psychiatric disorders. The present authors performed a systematic review and meta-analysis to estimate the prevalence of co-occurring psychiatric disorders, excluding co-occurring autism spectrum disorders, in subjects with intellectual disability.
METHOD: The present authors performed a random-effects meta-analysis of the prevalence of psychiatric disorders in adults and adolescents with intellectual disability.
RESULTS: Twenty-two studies were included. The pooled prevalence of any co-occurring psychiatric disorders in intellectual disability was 33.6% (95% CI: 25.2%-43.1%) with high heterogeneity but no publication bias. Prevalence was lower in population-based studies, in studies that used ICD criteria for the psychopathology and in studies with low risk of bias. The prevalence was higher in mild, moderate and severe intellectual disability than in profound intellectual disability.
CONCLUSIONS: Psychiatric disorders are common in subjects with intellectual disability, and the present authors found that clinical and methodological moderators affect the pooled prevalence.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  co-occurring psychiatric disorders; dual diagnosis; intellectual disability; meta-analysis

Mesh:

Year:  2019        PMID: 31430018     DOI: 10.1111/jar.12654

Source DB:  PubMed          Journal:  J Appl Res Intellect Disabil        ISSN: 1360-2322


  8 in total

1.  Mental, Neurological, and Somatic Comorbidities and Their Treatment in Persons With Intellectual Disability.

Authors:  Markus Weih; Sabine Köhler; Norbert Schöll; Mandy Schulz; Ramona Hering
Journal:  Dtsch Arztebl Int       Date:  2022-06-17       Impact factor: 8.251

2.  Differences in the support needs of children with developmental disabilities among groups of medical and behavioral needs.

Authors:  Victor B Arias; Virginia Aguayo; Miguel A Verdugo; Antonio M Amor
Journal:  PeerJ       Date:  2020-09-15       Impact factor: 2.984

3.  Trajectories of co-occurring psychopathology symptoms in autism from late childhood to adulthood.

Authors:  James B McCauley; Rebecca Elias; Catherine Lord
Journal:  Dev Psychopathol       Date:  2020-10

4.  Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review.

Authors:  Kazunari Yoshida; Emiko Koyama; Clement C Zai; Joseph H Beitchman; James L Kennedy; Yona Lunsky; Pushpal Desarkar; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2020-11-23       Impact factor: 5.321

5.  Cerebellar Agenesis and Bilateral Polimicrogyria Associated with Rare Variants of CUB and Sushi Multiple Domains 1 Gene (CSMD1): A Longitudinal Neuropsychological and Neuroradiological Case Study.

Authors:  Floriana Costanzo; Ginevra Zanni; Elisa Fucà; Margherita Di Paola; Sabina Barresi; Lorena Travaglini; Giovanna Stefania Colafati; Antonio Gambardella; Emanuele Bellacchio; Enrico Bertini; Deny Menghini; Stefano Vicari
Journal:  Int J Environ Res Public Health       Date:  2022-01-22       Impact factor: 3.390

6.  Exploring the victim offender overlap among people with an intellectual disability.

Authors:  Sophie Anstis; Stuart D M Thomas
Journal:  J Appl Res Intellect Disabil       Date:  2022-02-14

7.  Next-generation gene panel testing in adolescents and adults in a medical neuropsychiatric genetics clinic.

Authors:  Y Trakadis; A Accogli; B Qi; D Bloom; R Joober; E Levy; K Tabbane
Journal:  Neurogenetics       Date:  2021-08-07       Impact factor: 2.660

8.  Clinical Characteristics and Pharmacological Treatment of Individuals With and Without Intellectual Disability in Pre-trial Assessment-A Population-Based Study.

Authors:  Hanna Edberg; Qi Chen; Peter Andiné; Henrik Larsson; Tatja Hirvikoski
Journal:  Front Psychiatry       Date:  2020-10-23       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.